All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

EMA grants approval to mogamulizumab (Poteligeo®) for patients with previously treated cutaneous T-cell lymphoma

Dec 7, 2018

On 26 November 2018, mogamulizumab (Poteligeo®), a humanized monoclonal antibody directed against the CC chemokine receptor 4 (CCR4), received marketing authorization from the European Medicines Agency (EMA) for the treatment of adult patients with previously treated cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) or Sézary syndrome (SS), who have received at least one prior systemic therapy.

The approval granted by the EMA was based on positive results from the international, open-label, randomized, controlled, phase III MAVORIC trial (NCT01728805) comparing mogamulizumab with vorinostat in patients with previously treated MF and SS. Mogamulizumab therapy resulted in superior investigator-assessed progression-free survival in the intent-to-treat population compared with vorinostat therapy (median 7.7 months [95% CI, 5.7–10.3] versus 3.1 months [95% CI, 2.9–4.1] respectively, P < 0.0001).

The phase III trial investigators concluded that mogamulizumab could provide a new, effective treatment for patients with MF and, importantly, for SS, a subtype that represents a major therapeutic challenge in CTCL.

  1. Kyowa Hakko Kirin: Kyowa Kirin announces POTELIGEO® receives marketing authorisation in Europe for the treatment of Mycosis Fungoides and Sézary Syndrome. 2018 Nov 26. [Accessed 2018 Dec 7].
  2. Kim Y. H. et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled, phase 3 trial. Lancet. 2018 Aug 9; 19(9): 1192–1204. DOI: